Concert Pharma Receives a Buy from Stifel Nicolaus

By Austin Angelo

Stifel Nicolaus analyst Adam Walsh reiterated a Buy rating on Concert Pharma (NASDAQ: CNCE) yesterday and set a price target of $27. The company’s shares closed yesterday at $20.15.

According to TipRanks.com, Walsh is a 4-star analyst with an average return of 15.5% and a 57.1% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Vertex Pharmaceuticals, and Reata Pharmaceuticals.

Concert Pharma has an analyst consensus of Strong Buy, with a price target consensus of $26.25.

Based on Concert Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $144 million and quarterly net profit of $127 million. In comparison, last year the company earned revenue of $21K and had a GAAP net loss of $12.04 million.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2017, Ronald Barrett, a Director at CNCE sold 14,156 shares for a total of $349,653.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H.